Analysis of Mechanistic Pathway Models in Drug Discovery: p38 Pathway

Mechanistic models of signal transduction have emerged as valuable tools for untangling complex signaling networks and gaining detailed insight into pathway dynamics. The natural extension of these tools is for the design of therapeutic strategies. We have generated a novel computational model of lipopolysaccharide‐induced p38 signaling in the context of TNF‐α production in inflammatory disease. Using experimental measurement of protein levels and phospho‐protein time courses, populations of model parameters were estimated. With a collection of parameter sets, reflecting virtual diversity, we step through analysis of the p38 signaling pathway model to answer specific drug discovery questions regarding target prioritization, inhibitor simulation, model robustness and co‐drugging. We demonstrate that target selection cannot be assessed independently from inhibitor mechanism of action and is also linked with robustness to cellular variability. Finally, we assert that in the face of parameter uncertainty one can still uncover consistent findings that can guide drug discovery efforts.

[1]  K. S. Brown,et al.  Sloppy-model universality class and the Vandermonde matrix. , 2006, Physical review letters.

[2]  E. Pålsson-McDermott,et al.  Signal transduction by the lipopolysaccharide receptor, Toll‐like receptor‐4 , 2004, Immunology.

[3]  M. Gaestel,et al.  Leptomycin B‐sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation , 1998, The EMBO journal.

[4]  M. Fussenegger,et al.  A mathematical model of caspase function in apoptosis , 2000, Nature Biotechnology.

[5]  Avijit Ghosh,et al.  Automated oncogene detection in complex protein networks with applications to the MAPK signal transduction pathway. , 2005, Biophysical chemistry.

[6]  K. S. Brown,et al.  Statistical mechanical approaches to models with many poorly known parameters. , 2003, Physical review. E, Statistical, nonlinear, and soft matter physics.

[7]  M. Reichlin,et al.  The reactions of antibodies with hemeprotein antgens. The measurement of reaction kinetics and stoichiometry by fluorescence quenching. , 1969, The Journal of biological chemistry.

[8]  Michael U. Martin,et al.  Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. , 2002, Biochimica et biophysica acta.

[9]  S. Kimura,et al.  A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. , 2003, The Biochemical journal.

[10]  M. Fitzgibbon,et al.  Structure of Mitogen-activated Protein Kinase-activated Protein (MAPKAP) Kinase 2 Suggests a Bifunctional Switch That Couples Kinase Activation with Nuclear Export* , 2002, The Journal of Biological Chemistry.

[11]  G. K. Ackers,et al.  Kinetics of deoxyhemoglobin subunit dissociation determined by haptoglobin binding: estimation of the equilibrium constant from forward and reverse rates. , 1976, Biochemistry.

[12]  John G. Albeck,et al.  Cue-Signal-Response Analysis of TNF-Induced Apoptosis by Partial Least Squares Regression of Dynamic Multivariate Data , 2004, J. Comput. Biol..

[13]  D. Lauffenburger,et al.  Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.

[14]  A. Sherman,et al.  A mathematical model of metabolic insulin signaling pathways. , 2002, American journal of physiology. Endocrinology and metabolism.

[15]  D. Lauffenburger,et al.  A Systems Model of Signaling Identifies a Molecular Basis Set for Cytokine-Induced Apoptosis , 2005, Science.

[16]  A. Hoffmann,et al.  The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. , 2002, Science.

[17]  E. Roth,et al.  Influence of heat shock on cell volume regulation: protection from hypertonic challenge in a human monocyte cell line , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  P. Cohen,et al.  Feedback control of the protein kinase TAK1 by SAPK2a/p38α , 2003, The EMBO journal.

[19]  A. Hoffmann,et al.  The I (cid:1) B –NF-(cid:1) B Signaling Module: Temporal Control and Selective Gene Activation , 2022 .

[20]  D. Lauffenburger,et al.  Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity. , 2006, Systems biology.

[21]  A. Ghosh,et al.  A systems biology approach for the study of cumulative oncogenes with applications to the MAPK signal transduction pathway. , 2006, Biophysical chemistry.

[22]  Michael B. Yaffe,et al.  Data-driven modelling of signal-transduction networks , 2006, Nature Reviews Molecular Cell Biology.

[23]  S. Loewe The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[24]  E. Gilles,et al.  Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors , 2002, Nature Biotechnology.

[25]  H. Gutfreund,et al.  Reactions of Haemoglobin Dimers after Ligand Dissociation , 1970, Nature.

[26]  H. Okamoto Tumor necrosis factor inhibitors for rheumatoid arthritis. , 2006, The New England journal of medicine.

[27]  D. Lauffenburger,et al.  Applying computational modeling to drug discovery and development. , 2006, Drug discovery today.

[28]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[29]  C. Mirtsos,et al.  The Role of Interleukin 1 Receptor-associated Kinase-4 (IRAK-4) Kinase Activity in IRAK-4-mediated Signaling* , 2004, Journal of Biological Chemistry.

[30]  M. Gaestel,et al.  In the Cellular Garden of Forking Paths: How p38 MAPKs Signal for Downstream Assistance , 2002, Biological chemistry.

[31]  K. H. Lee,et al.  The statistical mechanics of complex signaling networks: nerve growth factor signaling , 2004, Physical biology.

[32]  C. L. Stokes,et al.  Effects of Bcl-2 levels on Fas signaling-induced caspase-3 activation: molecular genetic tests of computational model predictions , 2005, The Journal of Immunology.

[33]  G J Griffiths,et al.  Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. , 2006, Systems biology.